Cambridge College

Background and objectives: Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained in the 4-year CARE-MS extension, during which alemtuzumab-treated participants (‘alemtuzumab-only’) could receive additional courses upon disease activity, and IFN-treated participants switched to alemtuzumab (‘IFN-alemtuzumab’). Participants who completed the CARE-MS extension could enroll in the open-label TOPAZ study which assessed safety and efficacy for 5–7 years (11–13 years after alemtuzumab/IFN initiation). Methods: Participants received additional alemtuzumab courses as needed. Assessments included adverse events (AEs; primary outcome), annualized relapse rate (ARR), 6-month confirmed disability worsening [CDW; ⩾1.0-point Expanded Disability Status Scale (EDSS) score increase or ⩾1.5 if baseline EDSS = 0], and 6-month confirmed disease improvement [CDI; >1.0-point EDSS decrease (baseline score ⩾2.0)]. Results: 43.5% of alemtuzumab-only participants from CARE-MS II and 54.2% from CARE-MS I received no additional alemtuzumab courses; 30.0% and 20.9%, respectively, received one additional course (the median). Incidences of AEs, including thyroid AEs and infections, declined over time. The safety profile of alemtuzumab was similar for participants who received zero, one, or two additional courses. For CARE-MS II participants, who had inadequate response to previous treatment, ARR remained low during Years 3–13 for the alemtuzumab-only [0.17; 95% confidence interval (CI) 0.15–0.20] and IFN-alemtuzumab (0.14; 0.11–0.17) groups. At Year 11, the proportions of participants who were either free from CDW or who had CDI were higher in the alemtuzumab-only group (58% and 49%, respectively) than in the IFN-alemtuzumab group (51% and 37%). For CARE-MS I participants, who were previously treatment-naïve, clinical outcomes remained improved, and no between-group differences were apparent. Conclusion: Safety risks associated with alemtuzumab treatment declined over time. Clinical benefits were maintained up to 11–13 years, and most participants did not require more than one additional course. Clinicaltrials.gov identifiers: NCT00530348; NCT00548405; NCT00930553; NCT02255656

The market for virtual currencies in India rose from USD 926 a million during 2020 to USD 15 billion in January 2023. As reported by regulatory bodies, cryptocurrencies popularity has grown by eight hundred percent just this time last year. This study aims to find the effect of utility, user-friendliness of investment and effect of risk in trade on investors behavior (IB) with regard to cryptocurrencies. Digital currencies are an innovative kind of asset that has arisen. Because of its exceptional growth in value, Generation Y are turning to digital currencies as a means of investing. The Technology Acceptance Model is used in this article to investigate cryptocurrency uptake. A structured closed ended questionnaires are used to collect the responses. A user’s opinion is collected based on three parameters: utility, convenience with application, and safety. For collecting information, 185 investors were consulted by provided with questionnaires that they can complete the filling of responses by themselves. The respondents were chosen according to their readiness to participate in the survey. Convergent and discriminant Validity, reliability analysis and SEM model were used to analyze the data to find the results. The utility, utility, user-friendliness of investment and management of risk in trade are all having a major impact on behavioral patterns among investors while engage with cryptocurrency, according to the findings. This study contribution will help firms to comprehend users’ sensitivities with regard to cryptocurrencies and set various variables that influence its acceptance while delivering digital currency services to ease investment in better manner.